Also found in: Dictionary, Wikipedia.
Related to glimepiride: metformin


a sulfonylurea compound used as a hypoglycemic in treatment of type 2 diabetes mellitus; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Amaryl, Apo-Glimepiride (CA), CO Glimepiride (CA), Novo-Glimepiride (CA), PMS-Glimepiride (CA), Ratio-Glimepiride (CA), Sandoz Glimepiride (CA)

Pharmacologic class: Sulfonylurea

Therapeutic class: Hypoglycemic

Pregnancy risk category C


Lowers blood glucose level by stimulating insulin release from pancreas, increasing insulin sensitivity at receptor sites, and decreasing hepatic glucose production. Also increases peripheral tissue sensitivity to insulin and causes mild diuresis.


Tablets: 1 mg, 2 mg, 4 mg

Indications and dosages

Adjunct to diet and exercise to lower blood glucose level in type 2 (non-insulin-dependent) diabetes mellitus

Adults: Initially, 1 to 2 mg P.O. daily given with first main meal; usual maintenance dosage is 1 to 4 mg P.O. daily. When patient reaches 2 mg/day, increase no more than 2 mg q 1 to 2 weeks, depending on glycemic control. Maximum dosage is 8 mg/day.

Dosage adjustment

• Renal or hepatic impairment

• Adrenal or pituitary insufficiency


• Hypersensitivity to drug

• Diabetic coma or ketoacidosis

• Severe renal, hepatic, or endocrine disease

• Pregnancy or breastfeeding


Use cautiously in:

• mild to moderate hepatic or renal disease; cardiovascular disease; impaired thyroid, pituitary, or adrenal function

• elderly patients.


• Check baseline creatinine level for normal renal function before giving first dose.

• Give with first meal of day.

Adverse reactions

CNS: dizziness, drowsiness, headache, weakness

CV: increased CV mortality risk

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, cramps, heartburn, epigastric distress, anorexia

Hematologic: aplastic anemia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis

Hepatic: cholestatic jaundice, hepatitis

Metabolic: hyponatremia, hypoglycemia

Skin: rash, erythema, maculopapular eruptions, urticaria, eczema, angioedema, photosensitivity

Other: increased appetite


Drug-drug. Androgens (such as testosterone), chloramphenicol, clofibrate, guanethidine, MAO inhibitors, nonsteroidal anti-inflammatory drugs (except diclofenac), salicylates, sulfonamides, tricyclic antidepressants: increased risk of hypoglycemia

Beta-adrenergic blockers: altered response to glimepiride, necessitating dosage change; prolonged hypoglycemia (with nonselective agents)

Calcium channel blockers, corticosteroids, estrogens, hydantoins, hormonal contraceptives, isoniazid, nicotinic acid, phenothiazines, phenytoin, rifampin, sympathomimetics, thiazide diuretics, thyroid preparations: decreased hypoglycemic effect of glimepiride

Warfarin: initially increased, then decreased, effects of both drugs

Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, cholesterol, liver function tests: increased values

Glucose, granulocytes, hemoglobin, platelets, white blood cells: decreased values

Drug-herbs. Agoral marshmallow, aloe (oral), bitter melon, burdock, chromium, coenzyme Q10, dandelion, eucalyptus, fenugreek: additive hypoglycemic effects

Glucosamine: impaired glycemic control

Drug-behaviors. Alcohol use: disulfiram-like reaction

Sun exposure: increased risk of photosensitivity

Patient monitoring

• Monitor CBC with white cell differential, electrolyte levels, and blood chemistry results.

• Monitor blood glucose level regularly. Assess glycosylated hemoglobin level every 3 to 6 months.

• Evaluate kidney and liver function test results frequently, especially in patients with impairments.

• Assess neurologic status. Report cognitive or sensory impairment.

Patient teaching

• Instruct patient to self-monitor his blood glucose level as prescribed.

• Teach patient how to recognize signs and symptoms of hypoglycemia and hyperglycemia.

• Stress importance of diet and exercise to help control diabetes.

• Instruct patient to wear or carry medical identification describing his condition.

• Advise patient to keep sugar source readily available at all times in case of hypoglycemia.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Tell patient he will undergo regular blood testing during therapy.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A sulfonylurea drug, C24H34N4O5S, used to treat type 2 diabetes.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


An agent which may be used in combination with metformin (Glucophage) as 2nd-line therapy for type-2 diabetes when monotherapy with either Amaryl or metformin fail to achieve adequate blood glucose control.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.


Amaryl® Endocrinology An oral hypoglycemic sulfonurea used in type 2 DM, if hyperglycemia does not respond to diet and exercise Side effects Vertigo, asthenia, nausea, hypoglycemia
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


A SULPHONYLUREA drug used to treat maturity onset (Type II) DIABETES. A brand name is Amaryl.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Intergroup Comparison: Thus from the group I & II comparisons our finding is that adding glimepiride or repaglinide to the basic regime of M + losartan has increased advantage and favourable effect.
Comorbid cardiovascular disease###Prefer glimepiride gliclazide
Tablet dosage form (Tripill) contains an oral lipid lowering agent, atorvastatin, and two oral antihyperglycemic drugs, glimepiride and metformin hydrochloride.
Material and Methods: Patients with type 2 DM inadequately controlled with metformin monotherapy were randomized to receive sitagliptin 100mg or glimepiride 2mg once daily as add-on therapy for 12 weeks.
Notably, among the 2,721 subjects with documented coronary artery disease (CAD), glipizide and glyburide carried an increased overall mortality risk compared with metformin, but glimepiride did not, according to Dr.
"Overall, patients treated with a sulfonylurea had a mortality hazard ratio of 1.50 compared with metformin, including: glipizide -- HR 1.64, 95% CI 1.39 to 1.94; glyburide -- HR 1.59, 95% CI 1.35 to 1.88," and "glimepiride -- HR 1.68, 95% CI 1.37 to 2.06." Specifically, "the relative risk ranged from 59% with glyburide to 68% with glimepiride.
Additionally, among diabetes patients with heart disease, only glimepiride did not increase the risk of death compared to metformin.
A 52-week monotherapy phase 3 trial demonstrated a durable glycemic response to liraglutide alone compared with glimepiride 8 mg in 746 subjects previously treated with diet and exercise or OAD monotherapy.
The sulfonylureas were kindly supplied by the following manufacturers: glibenclamide, glimepiride, and tolbutamide by Aventis (Paris, France); glipizide and chlorpropamide by Pfizer (Paris, France); gliclazide and carbutamide by Servier (Neuilly-sur-Seine, France); glibornuride by CSP (Cournon, France); and glisoxepide by Bayer (Puteaux, France).
Michael Gottschalk, M.D., head of endocrinology at the University of California, San Diego, presented data on a 26-week, randomized, single-blind study comparing the safety and efficacy of glimepiride (Sanofi-Aventis' Amaryl) with metformin in 263 children aged 9-17 years with type 2 diabetes who were inadequately controlled (hemoglobin [A.sub.1c] 7.1%-12.0%) on diet and exercise alone or failed oral monotherapy (Hb[] greater than 7.5% for 3 or more months).
Amaryl is the trade name for glimepiride, which is approved for treating type 2 diabetes and is marketed by Aventis.